当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.

Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.

Abstract：

:This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6%) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1% for palpitations, 4.3% for angina, 3.5% for arterial hypertension, 3.0% for congestive heart failure, 1.8% for arrhythmia, 0.9% for AMI, 0.4% for pericardial effusion. CV-AEs led to treatment discontinuation in nine (3.9%) patients, while in the remaining cases they were managed by pharmacological intervention and/or patient life style improvement. CV-AEs had no relationship with patient characteristics (including older age). A significant relationship was found only with a higher anagrelide induction dose. In the absence of any agreed protocol, a cardiovascular instrumental evaluation (CV-IE) was performed in 102 (44%) patients before commencement of anagrelide (with higher rate after the anagrelide/Xagrid EMA approval of 2004), and in 84 (36%) patients during treatment. Patients with and without CV-IEs, who resulted completely balanced for all their characteristics, did not significantly differ in the occurrence of CV-AEs. In conclusion, this study on ET patients treated with anagrelide shows that CV-AEs, equally distributed in younger and older subjects, were mostly mild and easily manageable, allowing safe treatment continuation in the majority of cases. Moreover, routinely performing a CV-IE did not appear to anticipate the occurrence of CV-AEs.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Gugliotta L,Tieghi A,Tortorella G,Scalzulli PR,Ciancia R,Lunghi M,Cacciola E,Cacciola R,Candoni A,Crugnola M,Codeluppi K,Usala E,Specchia G,Martinelli V,Palmieri F,Pierri I,Liberati AM,Iurlo A,Grossi A,Vannucchi AM

doi

10.1016/j.leukres.2011.06.030

subject

Has Abstract

pub_date

2011-12-01 00:00:00

pages

1557-63

issue

12

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(11)00320-1

journal_volume

35

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Enhancement of J6-1 human leukemic cell proliferation by membrane-bound M-CSF through a cell-cell contact mechanism II. Role of an M-CSF receptor-like membrane protein.

    abstract：:We have isolated an M-CSF-like membrane-associated growth factor from human leukemic J6-1 cells that can enhance the growth and colony formation of J6-1 cells in vitro. Indirect evidence suggests that this membrane-associated M-CSF-like growth factor may do so by stimulating a corresponding receptor co-expressed on th...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(97)00135-5

    authors： Wu KF,Rao Q,Zheng GG,He ZH,Ying HG,Song YH,Chen BD

    更新日期：1998-01-01 00:00:00

  • Metabolism of chylomicron-like emulsions in patients with Hodgkin's and with non-Hodgkin's lymphoma.

    abstract：BACKGROUND:Chylomicrons carry in the bloodstream dietary fats absorbed the intestine for storage in the body tissues such as adipose and muscle. The two-step chylomicron metabolism consists in lipolysis by lipoprotein lipase on vessel walls and hepatic uptake of triglyceride-depleted remnants. Chylomicron metabolism is...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(02)00087-5

    authors： Gonçalves RP,Hungria VT,Chiattone CS,Pozzi DB,Maranhão RC

    更新日期：2003-02-01 00:00:00

  • Differential effect of heat shock on RNA metabolism in human Burkitt's lymphoma B-cell lines.

    abstract：:Thermal stress induces expression of a family of heat shock proteins which may regulate the synthesis of various cellular genes. We investigated the effect of heat shock on polyadenylation in Epstein-Barr Virus (EBV) negative and EBV transformed human Burkitt's lymphoma (BL) B-cell lines. Incubation of the BL B-cell l...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(95)00063-1

    authors： Kumar A,Kurl RN,Kryworuchko M,Diaz-Mitoma F,Sharma S

    更新日期：1995-11-01 00:00:00

  • Clinical and molecular aspects of Turkish familial hemophagocytic lymphohistiocytosis patients with perforin mutations.

    abstract：:The aim of this study was to elucidate the pathologic sequence changes and associated clinical phenotypes in 9 new patients showing homozygosity for perforin gene among a total of 37 (24%) Turkish FHL families studied by linkage analysis. These 9 unrelated patients (5M/4F) were coming from consanguineous families and ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.11.033

    authors： Okur H,Balta G,Akarsu N,Oner A,Patiroglu T,Bay A,Sayli T,Unal S,Gurgey A

    更新日期：2008-06-01 00:00:00

  • ELF4 is fused to ERG in a case of acute myeloid leukemia with a t(X;21)(q25-26;q22).

    abstract：:We report a novel chromosomal translocation in AML, t(X;21)(q25-26;q22), resulting in a fusion transcript between two ETS domain family members, ELF4 (at Xq25) and ERG (at 21q22). ERG has been associated previously with other fusion partners, specifically FUS and EWSR1, and implicated in both AML and Ewing's sarcoma. ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.10.014

    authors： Moore SD,Offor O,Ferry JA,Amrein PC,Morton CC,Dal Cin P

    更新日期：2006-08-01 00:00:00

  • Good riddance to the term "refractory anemia" in myelodysplastic syndromes.

    abstract：:The term "refractory anemia" was used in 1937 by Cornelius Parker Rhoads to describe patients whose anemia did not improve after treatment with liver extract or iron salts, and this term has been used to denote patients with certain subtypes of myelodysplastic syndromes (MDS) since the 1976 and 1982 French-American-Br...

    journal_title：Leukemia research

    pub_type： 历史文章,杂志文章

    doi：10.1016/j.leukres.2016.10.007

    authors： Steensma DP

    更新日期：2016-12-01 00:00:00

  • Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.

    abstract：:Appropriate treatment for nonreactive thrombocytosis resulting from a myeloproliferative disorder (MPD) is surrounded by controversy. Although few doubt the association of thrombocytosis with increased risk for life-threatening events such as thrombosis or hemorrhage, or the association between clonal myeloproliferati...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2004.10.002

    authors： Fruchtman SM,Petitt RM,Gilbert HS,Fiddler G,Lyne A,Anagrelide Study Group.

    更新日期：2005-05-01 00:00:00

  • Cytotoxic responses to BLV tax oncoprotein do not prevent leukemogenesis in sheep.

    abstract：:Delta retrovirus-mediated leukemogenesis is dependent on the oncogenic potential of Tax. It is not clear, however, whether Tax-specific immune responses play a role in leukemia onset and progression. Using the BLV-associated leukemia model in sheep, we found that Tax-specific cytotoxic responses induced by DNA immuniz...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.06.003

    authors： Van den Broeke A,Oumouna M,Beskorwayne T,Szynal M,Cleuter Y,Babiuk S,Bagnis C,Martiat P,Burny A,Griebel P

    更新日期：2010-12-01 00:00:00

  • Treatment of human T-cell acute lymphoblastic leukemia cells with CFTR inhibitor CFTRinh-172.

    abstract：:Our previous studies have demonstrated that a previously unrecognized role of CFTR in hematopoiesis and acute leukemia. Here, we show that CFTR inhibitor CFTR-inh172 possesses ability to inhibit human T-cell acute lymphoblastic leukemia cells. In detail, CFTR-inh172 inhibited cell proliferation, promoted apoptosis and...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2019.106225

    authors： Liu M,Liao H,Chen Y,Lin Z,Liu Y,Zhang X,Chan HC,Sun H

    更新日期：2019-11-01 00:00:00

  • Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).

    abstract：:We investigated the role of Src family kinases (SFKs) in the regulation of STAT activation in myeloid leukemia cells. Two of 6 AML cell lines displayed constitutive STAT5 activation, whereas four cell lines had constitutive SFK activity. Treatment with the SFK inhibitors suppressed STAT5 activation and decreased viabi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.11.032

    authors： Ozawa Y,Williams AH,Estes ML,Matsushita N,Boschelli F,Jove R,List AF

    更新日期：2008-06-01 00:00:00

  • The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes.

    abstract：:During 2004-2006, two hypomethylating agents (HMAs) were approved for the treatment of myelodysplastic syndromes (MDS) in the United States. We assessed the impact of HMAs on the cost of care and survival of MDS patients, by constructing a cohort of patients who were diagnosed during 2001-2007 (n=6556, age ≥66.5 years...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.07.020

    authors： Wang R,Gross CP,Frick K,Xu X,Long J,Raza A,Galili N,Zikria J,Guan Y,Ma X

    更新日期：2012-11-01 00:00:00

  • Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency.

    abstract：:Mutation of the tumor suppressor PTEN results in loss of its PI3-kinase counteracting function. PI3-kinase stimulates tumor formation by PKB/Akt-mediated cell proliferation and prevention of apoptosis. PI3-kinase may also activate Rho-GTPases and their regulatory GEFs to promote invasion. Here we have analyzed the fun...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.03.034

    authors： Strumane K,Song JY,Baas I,Collard JG

    更新日期：2008-01-01 00:00:00

  • Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia.

    abstract：:We wondered whether there was any association between the extent of increased angiogenesis and IgV(H) gene mutational status, expression of CD38 and ZAP-70 in early B-cell chronic lymphocytic leukemia (CLL) patients. Circulating levels of vascular endothelial growth factor (VEGF) correlated positively with ZAP-70-expr...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.03.009

    authors： Molica S,Cutrona G,Vitelli G,Mirabelli R,Molica M,Digiesi G,Ribatti D,Ferrarini M,Vacca A

    更新日期：2007-11-01 00:00:00

  • Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma.

    abstract：:The ubiquitin-proteasome pathway is implicated in the pathogenesis of many haematologic malignancies, including multiple myeloma. Under conditions of rapid cell turnover and growth rate, proteasomes are returned into circulation. The measurement of their levels or activity could offer a new approach to diagnosis, prog...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2014.05.008

    authors： Oldziej A,Bolkun L,Galar M,Kalita J,Ostrowska H,Romaniuk W,Kloczko J

    更新日期：2014-08-01 00:00:00

  • Survival in acute myeloblastic leukemia is not prolonged by remission maintenance or early reinduction chemotherapy. The Toronto Leukemia Study Group.

    abstract：:A role for post-induction chemotherapy for adult patients with acute myeloblastic leukemia in remission has not been established. We have studied 125 patients with acute myeloblastic leukemia in complete remission to determine the effect on survival of remission maintenance therapy and of early reinduction therapy giv...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/0145-2126(88)90136-1

    authors：

    更新日期：1988-01-01 00:00:00

  • Prognostic classification of patients with acute lymphoblastic leukemia by using gene copy number profiles identified from array-based comparative genomic hybridization data.

    abstract：:The development of risk-adapted therapy has improved the treatment results of acute lymphoblastic leukemia (ALL) especially in children. However, more accurate risk classifiers are warranted. In this study we aimed at defining a prognostic classifier based on DNA copy number alterations of adolescent and young adult (...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.02.031

    authors： Usvasalo A,Elonen E,Saarinen-Pihkala UM,Räty R,Harila-Saari A,Koistinen P,Savolainen ER,Knuutila S,Hollmén J

    更新日期：2010-11-01 00:00:00

  • KN-62 analogues as potent differentiating agents of HL-60 cells.

    abstract：:KN-62, an inhibitor of the calmodulin-dependent protein kinases (CaMKs), enhances the terminal differentiation of retinoic acid sensitive human myeloid leukemia cell lines. In an effort to identify additional CaMK inhibitors that exhibit more potent activity in triggering leukemia cell differentiation, we synthesized ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.07.022

    authors： Schuler AD,Si J,Mueller L,Simon JA,Collins SJ

    更新日期：2007-05-01 00:00:00

  • Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.

    abstract：:Selective inhibition of the BCR/ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is the therapeutic strategy in patients with chronic myelogenous leukemia (CML). Despite significant hematologic and cytogenetic responses with imatinib, mainly due to the mutations in the Abl kinase domain, resistance occurs in p...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.11.007

    authors： Arunasree KM,Roy KR,Anilkumar K,Aparna A,Reddy GV,Reddanna P

    更新日期：2008-06-01 00:00:00

  • Molecular characterization and prognostic significance of FLT3 in CML progression.

    abstract：:To characterize the molecular mechanisms involved in the transition from the chronic phase to blast crisis in chronic myelogenous leukemia (CML), gene expression profiles of leukemic cells from patients in the chronic and blast crisis phases were analyzed using an 8.7K cDNA chip and real-time PCR. A transient transfec...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.11.008

    authors： Kim KI,Park J,Ahn KS,Won NH,Kim BK,Shin WG,Yoon SS,Oh JM

    更新日期：2010-08-01 00:00:00

  • 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma.

    abstract：:Standard chemotherapic approach for MZL is missing. We are presenting our monocenter experience with 2CdA+/-rituximab. Patients received 2CdA, 5mg/m(2), weekly, for 6 weeks. Patients receiving rituximab underwent to antibody administration in association with 2CdA, or after the end of chemotherapy. Global ORR was 89.3...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.leukres.2009.04.003

    authors： Orciuolo E,Buda G,Sordi E,Baraté C,Galimberti S,Ciancia E,Petrini M

    更新日期：2010-02-01 00:00:00

  • Clinical spectrum of gammadelta+ T cell LGL leukemia: analysis of 20 cases.

    abstract：:We report on the clinico-biological characteristics of 20 cases of gammadelta T cell large granular lymphocyte (LGL) leukemia. All the data were compared to that of 196 cases with alphabeta T cell subtype, which represents the majority of T cell LGL leukemias. Clinical findings were quite similar in the two groups reg...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.04.011

    authors： Bourgault-Rouxel AS,Loughran TP Jr,Zambello R,Epling-Burnette PK,Semenzato G,Donadieu J,Amiot L,Fest T,Lamy T

    更新日期：2008-01-01 00:00:00

  • The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.

    abstract：:HSP90 is a multi-client chaperone involved in regulating a large array of cellular processes and is commonly overexpressed in many different cancer types including hematological malignancies. Inhibition of HSP90 holds promise for targeting multiple molecular abnormalities and is therefore an attractive target for hete...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.03.016

    authors： Lazenby M,Hills R,Burnett AK,Zabkiewicz J

    更新日期：2015-06-01 00:00:00

  • Morphological comparison of dysplastic changes between de novo acute myeloid leukemia (AML) with trilineage myelodysplasia and AML developed from de novo myelodysplastic syndromes.

    abstract：:To elucidate the clinical and morphological differences between de novo acute myeloid leukemia (AML) with trilineage myelodysplasia (AML/TMDS) and AML developed from de novo myelodysplastic syndrome (MDS), we analyzed 12 and 13 cases, respectively. The median age of AML/TMDS patients was lower, but not significantly s...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(94)00134-v

    authors： Kuriyama K,Miyazaki Y,Arimura K,Nagai K,Nakamura H,Matsuo T,Tomonaga M

    更新日期：1995-02-01 00:00:00

  • New therapeutics for myelodysplastic syndromes.

    abstract：:While MDS was only recently viewed as an orphan disease without any FDA approved therapeutic options, the landscape has changed dramatically with a promise for development of exciting new therapeutics that parallels our growing understanding of the pathobiology of the disease. An array of new agents is entering clinic...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2012.08.010

    authors： List AF

    更新日期：2012-12-01 00:00:00

  • ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target.

    abstract：:Nasal-type natural killer/T-cell (NK/T-cell) lymphomas are subtypes of non-Hodgkin's lymphoma (NHL), which are typically more clinically aggressive. There is, however relatively little understanding of nasal-type NK/T-cell lymphoma molecular pathogenesis. Thus, in this study we applied RNA sequencing to systematically...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.10.001

    authors： Zhang X,Zhao L,Li X,Wang X,Li L,Fu X,Sun Z,Li Z,Nan F,Chang Y,Zhang M

    更新日期：2015-12-01 00:00:00

  • Functional analysis of the SEPT9-ABL1 chimeric fusion gene derived from T-prolymphocytic leukemia.

    abstract：:We analyzed the function of a SEPT9-ABL1 fusion identified in a case of T-prolymphocytic leukemia with tyrosine kinase inhibitor (TKI) resistance. Five isoforms with different N-termini, including SEPT9a-ABL1, SEPT9b-ABL1, SEPT9d-ABL1, SEPT9e-ABL1 and SEPT9f-ABL1, were detected in the leukemic cells. All isoforms exce...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2014.08.015

    authors： Kawai H,Matsushita H,Suzuki R,Sheng Y,Lu J,Matsuzawa H,Yahata T,Tsuma-Kaneko M,Tsukamoto H,Kawada H,Ogawa Y,Ando K

    更新日期：2014-12-01 00:00:00

  • Effects of cytapheresis on cell cycle distribution of peripheral blood and bone marrow cells in some hematological malignancies.

    abstract：:Feulgen-DNA cytophotometry and 3H-thymidine autoradiography were used to evaluate therapeutic cytapheresis effects on cell cycle distributions of peripheral blood leukemic cells in 15 acute leukemia, 5 CML and 8 CLL patients and of bone marrow erythroblasts in 18 PV patients. Both individual cytapheresis procedures an...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90186-x

    authors： Kotelnikov VM,Kasatkina VV,Dultsina SM,Sarytcheva TG,Kalinin NN,Kovaleva LG,Poljanskaja AM,Isajev VG,Khoroshko ND,Lishmanova NG

    更新日期：1987-01-01 00:00:00

  • A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naïve T cells.

    abstract：:We established a plasmacytoid dendritic cell (pDC) line (PMDC05) from leukemia cells of pDC leukemia. PMDC05 cells were positive for CD4, CD56, CD33, HLA-DR, CD123 (IL-3Ralpha) and CD86 in the absence of lineage markers. mRNA of TLR1, TLR2, TLR4, TLR7 and TLR9 was clearly expressed and among these TLRs, TLR7 was promi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.03.047

    authors： Narita M,Watanabe N,Yamahira A,Hashimoto S,Tochiki N,Saitoh A,Kaji M,Nakamura T,Furukawa T,Toba K,Fuse I,Aizawa Y,Takahashi M

    更新日期：2009-09-01 00:00:00

  • Dimethyl sulfoxide potentiates death receptor-mediated apoptosis in the human myeloid leukemia U937 cell line through enhancement of mitochondrial membrane depolarization.

    abstract：:Dimethyl sulfoxide (DMSO) is a widely used prototypical chemical inducer of cell differentiation. In the present study, the effects of DMSO on susceptibility of human myeloid leukemia U937 cells towards ligation of distinct death receptors (DRs) were investigated. DMSO sensitized cells towards induction of apoptosis b...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.05.016

    authors： Vondrácek J,Soucek K,Sheard MA,Chramostová K,Andrysík Z,Hofmanová J,Kozubík A

    更新日期：2006-01-01 00:00:00

  • Mouse monoclonal antibodies direct phagocytosis of tumor cells by human monocytes.

    abstract：:Human peripheral blood monocytes were found to be capable of phagocytizing human B-non Hodgkin's lymphoma (NHL) cells coated with mouse monoclonal antibodies (MoAbs). The MoAbs used recognized idiotypic determinants on the surface immunoglobulin (Ig) of the tumor cells. MoAbs of IgG1 and IgG2a subclass were equally ef...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(86)90344-9

    authors： Calafat J,Janssen H,Hekman A

    更新日期：1986-01-01 00:00:00